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ABSTRACT
Objectives: COVID-19 predisposes patients to thrombotic disease. The aim of this guidance 
document is to provide Belgian health-care workers with recommendations on anticoagulation 
management in COVID-19 positive patients.
Methods: These recommendations were based on current knowledge and a limited level of 
evidence.
Results: We formulated recommendations for the prophylaxis and treatment of COVID-related 
venous thromboembolism in ambulatory and hospitalised patients, as well as recommenda-
tions for the use of antithrombotic drugs in patients with prior indication for anticoagulation 
who develop COVID-19.
Conclusions: These recommendations represent an easy-to-use practical guidance that can be 
implemented in every Belgian hospital and be used by primary care physicians and gynaecol-
ogists. Of note, they are likely to evolve with increased knowledge of the disease and avail-
ability of data from ongoing clinical trials.
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1. Background and challenges
COVID-19, a viral respiratory illness caused by the 
severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) [1], may predispose patients to thrombo-
tic disease, both in the venous and arterial circulation, 
due to excessive inflammation, platelet activation, 
endothelial dysfunction, and stasis [2–4]. Indirect 
effects of infection, e.g. severe inflammatory response, 
critical illness, and traditional risk factors may also 
contribute to risk for thrombotic disease/events [3]. In 
addition, many patients receiving antithrombotic ther-
apy may develop COVID-19, which can have implica-
tions for choice, dosing, and laboratory monitoring of 
antithrombotic therapy [3].
Venous thromboembolism (VTE) has been reported 
in 25% to 69% of patients with severe COVID-19 in the 
intensive care unit, and is associated with poor prog-
nosis/morbidity and mortality [5–10]. A French study 
showed an increased rate of CT-scan detected pulmon-
ary embolism in ICU COVID-19 patients compared to 
the usual rate encountered in critically ill non-COVID 
-19 patients [11]. Laboratory findings indicate that 
markers of coagulopathy, including elevated 
D-dimers and prolonged prothrombin time, are linked 
to more severe disease and a higher mortality [2,12– 
15]. Several case series also describe an increased risk 
of arterial thrombosis and of microvascular organ 
damage, including pulmonary intravascular coagula-
tion [16] as well as widespread pulmonary thrombosis 
[17]. Furthermore, a non-randomized study showed 
a lower mortality in COVID-19 patients who used 
thromboprophylaxis as compared to patients who 
did not receive antithrombotic therapy, particularly in 
patients with elevated D-dimers [18]. Another retro-
spective study indicated that the use of therapeutic 
anticoagulation was associated with lower in-hospital 
mortality [19], but neither the indication for anticoa-
gulation nor the type of treatment was described.
The American Society of Hematology and the 
International Society for Thrombosis and Hemostasis 
recommended to institute venous thromboembolism 
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prophylaxis measures for patients at risk [3,20]. 
Nevertheless, the choice and dose of thromboprophy-
laxis remain controversial [21–23].
Low molecular weight heparin (LMWH) is the 
recommended therapy for pharmacological thrombo-
prophylaxis in critically ill patients, with the exception 
of patients with severe renal dysfunction (for whom 
unfractionated heparin could be considered based on 
a careful risk/benefit assessment) and patients with 
a history of heparin-induced thrombocytopenia 
[24,25]. In the latter, fondaparinux is an alternative 
drug for the prevention or treatment of thrombosis, 
although it is not reimbursed for hospitalised patients 
in Belgium. Several experimental antivirals used to 
treat COVID-19 may increase plasma levels of direct 
oral anticoagulant (DOAC) because of P-glycoprotein 
inhibition and/or competition, inhibition or induction 
of CYP3A4-dependent pathways [26]. Therefore, par-
enteral LMWH is the preferred agent for thrombopro-
phylaxis [26]. Although interim guidelines agree on the 
choice of thromboprophylaxis, the optimal anticoagu-
lant dose in COVID-19 in patients is unknown; inter-
mediate- or full-dose regimens rather than 
prophylactic doses have been suggested but higher 
doses also cause more bleeding [3,27].
Furthermore, given the high incidence of VTE even 
despite thromboprophylaxis [9], a clear strategy for the 
treatment of newly diagnosed VTE in the context of 
COVID-19 is required. Finally, the optimal management 
of patients who require therapeutic anticoagulation 
because of a pre-existing indication (atrial fibrillation, 
mechanical heart valves, history of VTE) is unknown.
Algorithms for the management of coagulopathy in 
COVID-19 patients have been produced in order to 
provide answers to urgent clinical needs across the 
world [28]. Due to local specificities, it is however 
mandatory that every country or area formulates 
recommendations that easily apply to the regional 
health-care setting.
2. Methods
These guidelines were developed by a Belgian 
Working Group gathering members of the Belgian 
Society on Thrombosis and Haemostasis council 
belonging to Belgian University Hospitals, general 
practitioners and gynaecologists, in collaboration 
with the Belgian Health Care Knowledge Center (KCE, 
https://kce.fgov.be) and Sciensano. The recommenda-
tions were based on published reports (MEDLINE 
PubMed) and local experience, in accordance with 
most recent guidance from Scientific and 
Standardization Committee Communication of the 
International Society on Thrombosis and Haemostasis 
[20] and the American anticoagulation forum [29]. 
Given the time-sensitive nature of the challenges 
encountered during COVID-19 pandemia, the majority 
of existing data are based on retrospective and often 
single-center small studies. There are no published or 
completed prospective cohort studies or randomized 
controlled trials. This has important implications for 
the recommendations presented herein, which mainly 
rely on limited level of evidence and are likely to evolve 
with knowledge of COVID-19 pathophysiology and 
availability of data from ongoing clinical trials.
3. Recommendations
We formulated recommendations, including sche-
matic algorithms, on anticoagulation management 
in hospitalised COVID-19 patients and after dis-
charge (Figure 1), and on anticoagulation manage-
ment in non-hospitalised COVID-19 patients 
(Figure 2).
Recommendations for anticoagulation manage-
ment during pregnancy and post-partum period in 
COVID-19 positive women were also included.
3.1. Anticoagulation management in hospitalised 
COVID-19 patients and after discharge
3.1.1. General consideration
The guidelines apply to most patients. However, in 
patients at high risk of bleeding (e.g., platelet count < 
50x103/μl, recent major bleeding, dialysis or frail 
elderly patients), we recommend that the risks and 
benefits of thromboprophylaxis should be weighed 
on an individual basis.
Figure 1. Anticoagulation management in hospitalised COVID- 
19 patients and after discharge.
Figure 2. Anticoagulation management in non-hospitalised 
COVID-19.
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3.1.2. At admission
We emphasize the importance of a low threshold of 
clinical suspicion of VTE at diagnosis and during the 
whole duration of the hospitalisation period.
We highly recommend that patients with a prior 
indication for anticoagulation (e.g., atrial fibrillation, 
VTE, mechanical heart valve) should continue to 
receive anticoagulation. We recommend switching to 
LMWH instead of oral anticoagulation (vitamin 
K antagonist or DOAC) in the following cases: severely 
ill patients, patients with gastro-intestinal problems, 
planned invasive procedures, patients with unstable 
INRs and/or presence of potential drug–drug interac-
tions, including antivirals and immunomodulatory 
investigational therapies [26,30].
We recommend administering prophylactic antic-
oagulation of LMWH in patients who have no prior 
indication for anticoagulation and no VTE at admission.
3.1.3. Anticoagulation regimen in patients with 
a prior indication for anticoagulation
For hospitalised patients with an established indication 
for therapeutic anticoagulation (e.g., atrial fibrillation, 
VTE, mechanical heart valve), we recommend conti-
nuation of anticoagulation in therapeutic doses.
If oral anticoagulation is switched to parenteral 
treatment, we recommend a therapeutic dose of 
LMWH of 100 anti-Xa IU/kg twice-daily (i.e. 1 mg/kg 
enoxaparin twice-daily) in patients with a high risk of 
thrombotic complications (mechanical heart valves, 
recent VTE, high-risk thrombophilia, or atrial fibrillation 
[31]). In patients with a lower risk of thrombotic com-
plications (secondary prevention of VTE without high- 
risk thrombophilia), we suggest using either LMWH 
therapeutic dose or high intermediate dose of LMWH 
based on the severity of the disease and of the bleed-
ing risk. The dose should be adjusted to renal function. 
In patients with Cockroft (CrCl) <30 ml/min, we recom-
mend dose-adjusted therapeutic LMWH or tinzaparin, 
while patients with CrCl <15 ml/min should receive 
unfractionated heparin with appropriate monitoring 
(anti-Xa monitoring may be preferred over aPTT mon-
itoring in critically ill patients) or adjusted LMWH with 
careful monitoring of anti-Xa, taking into account local 
expertise and experience.
3.1.4. Anticoagulation regimen for 
thromboprophylaxis in hospitalised patients with 
COVID-19
For patients who are not in intensive care unit (ICU), we 
recommend a weight-adjusted LMWH prophylactic 
dose with a minimum of 50 anti-Xa IU/kg once-daily, 
irrespective of renal function. Several studies indeed 
suggest that a standard fixed VTE prophylaxis dose 
may not be appropriate in patients at extremes of 
weight [32].
For ICU patients, we recommend a high- 
prophylactic anticoagulation regimen with 50 anti-Xa 
IU/kg twice-daily for patients with CrCl >30 mL/min. 
For patients with CrCl <30 mL/min, we suggest to use 
a reduced dose of 50 anti-Xa IU/kg once-daily. In the 
case of severe renal dysfunction (CrCl <15 mL/min), we 
suggest the use of unfractionated heparin or anti-Xa 
monitoring. This recommendation is based on several 
reports of case series indicating VTE incidence reaching 
up to 27% in critically ill COVID-19 patients with pneu-
monia, despite standard-dose thromboprophylaxis 
[5,6,9], and on preliminary clinical data suggesting 
that either use of prophylactic or intermediate dose 
of LMWH in patients with high SIC (sepsis-associated 
coagulopathy) score (≥4) or high D-dimers (>6 times 
ULN) was associated with better prognosis [18].
Notwithstanding, a recent study highlights that 
major bleeding rates may be higher than initially 
thought (5.6% in critically ill patients), while VTE rate 
was far lower (7.6% in critically ill patients), therefore 
suggesting that empiric intensifying of anticoagulation 
in these patients should be pursued with caution [33]. 
The potential benefit of intensified anticoagulation 
needs to be evaluated in ongoing randomized clinical 
trials [34]***. Therefore, we recommend that therapeu-
tic anticoagulation is restricted to patients with prior 
indication for therapeutic anticoagulation or patients 
with confirmed VTE. Therapeutic anticoagulation in 
patients with COVID-19 might be associated with 
improved outcomes in selected very severely ill 
patients, especially patients under mechanical ventila-
tion, but this has to be put in balance with bleeding 
risks. Hence, we recommend to restrict the use of 
therapeutic anticoagulation in patients without clear 
indication to clinical trial protocols.
3.1.5. Anticoagulation regimen for the treatment 
of COVID-19-related VTE
For COVID-19 patients who develop VTE during hospi-
talisation, we recommend treatment with therapeutic 
doses of LMWH (100 anti-Xa IU/kg twice-daily). In 
patients with CrCl <30 ml/min, dose-adjusted thera-
peutic LMWH or tinzaparin should be considered. In 
patients with CrCl <15 ml/min, we recommend the use 
of unfractionated heparin or anti-Xa monitoring.
3.1.6. D-dimer
We do not recommend to routinely adapt the antic-
oagulation regimen based on D-dimer levels. Indeed, 
elevated D-dimers levels are a common finding in 
COVID-19 [30,35], which correlates with inflammation; 
they appear to be useful markers of poor overall out-
come [2,12,13].
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However, clinical suspicion, guided by clinical signs 
and symptoms, changing cardiopulmonary status, and, 
possibly, abruptly changing D-dimer levels should be 
used to guide the decision to rule out or in VTE with 
validated algorithms [36].
3.1.7. Screening for VTE
Systematic screening for VTE in COVID-19 positive 
patients is not recommended but there should be an 
increased awareness for VTE during hospitalisation 
(e.g., look for clinical signs like swollen leg, hypoxemia 
non-proportionate to the respiratory status, acute right 
ventricle failure or dilation, catheter issues).
There should be a low threshold to perform imaging 
whenever VTE is suspected. When strongly suspected, 
we suggest therapeutic anticoagulation especially in 
the ICU when it is not possible to obtain confirmation 
by imaging.
3.1.8. Anti-Xa monitoring
We do not recommend performing systematic moni-
toring of LMWH. It is however suggested to perform an 
anti-Xa assay when there is a suspicion of accumula-
tion of LMWH (and thus increased risk of bleeding) in 
the following circumstances: patients with extreme 
body weight (BMI< 18 or BMI >30 kg/m2) or renal 
insufficiency or in patients with a bleeding diathesis.
3.1.9. Anticoagulation management at discharge
We recommend to routinely evaluate the need for 
anticoagulation after discharge.
In patients with a prior/established indication for 
anticoagulation, we recommend switching back to 
the initial oral anticoagulation medication and regi-
men unless oral therapy is not feasible, e.g. due to 
drug–drug interaction issues [26].
In patients who developed VTE during the hospita-
lization period, we recommend continuing therapeutic 
LMWH until outpatient control. Switching to oral ther-
apy, i.e. DOAC, can be considered in selected patients 
who are in good general condition and no longer have 
symptoms of COVID-19. The duration of therapeutic 
anticoagulation should be at least 3 months.
In patients without a prior indication for therapeutic 
anticoagulation who received thromboprophylaxis dur-
ing hospitalisation, a 2-week standard post-discharge 
LMWH thromboprophylaxis (50 anti-Xa IU/kg once- 
daily) should be considered. If additional risk factors for 
VTE are present (e.g., ICU stay, known thrombophilia, 
obesity, high-dose estrogen use, immobilization, heart 
failure, respiratory failure, age >70 years, active cancer, 
personal or familial history of VTE and/or major surgery 
in the last 3 months) we suggest extended thrombopro-
phylaxis for 4 to 6 weeks after discharge. Continuation of 
thromboprophylaxis should be discussed according to 
risk-benefit balance (mobility/bleeding risk and other 
risk factors).
In order to limit contacts with health-care workers 
when the patients are back home, it can be considered 
to switch LMWH to a DOAC if the patient is eligible and 
needs continued anticoagulation, has good oral intake 
and good renal function. If this is not possible, self- 
administration should be encouraged.
3.2. Anticoagulation management in 
non-hospitalised COVID-19 patients
3.2.1. General considerations
The following guidelines apply to most non- 
hospitalised patients. However, in patients at high 
risk of bleeding (e.g., platelet count < 50x103/μl, recent 
major bleeding, dialysis or frail elderly patients), we 
recommend that the risks and benefits of thrombopro-
phylaxis should be weighed on an individual basis.
Whenever possible, mobilisation should be encour-
aged to reduce the risk of VTE. In any case, we recom-
mend being aware of signs and symptoms of VTE. In the 
case of suspected VTE, the patient should be referred for 
appropriate diagnostic testing. While awaiting results of 
diagnostic testing, initiation of therapeutic anticoagula-
tion can be considered if clinical suspicion is high and 
bleeding risk is low. If LMWH administration is needed at 
home, self-administration is encouraged in order to 
avoid contact with health-care workers.
3.2.2. Patients in need of long-term 
anticoagulation
In patients treated with vitamin K-antagonist therapy, 
we recommend against changing the standard of care, 
as long as the patient has good oral intake and stable 
INRs.
In patients under chronic DOAC or LMWH therapy, 
control of renal function should be considered in 
patients with prior renal impairment or in patients 
with high fever, gastrointestinal symptoms and/or 
reduced intake.
3.2.3. Patients without known VTE or any other 
indication for long-term anticoagulation
In COVID-19 positive patients who are asymptomatic 
or mildly symptomatic, we recommend against pro-
phylactic anticoagulation in the ambulatory setting.
In COVID-19 patients who are severely ill and who 
are immobilised (bedridden), we recommend LMWH 
prophylaxis when additional risk factors for VTE are 
present: known thrombophilia, personal or familial 
history of VTE, obesity, pregnancy, heart failure, 
respiratory failure age >70 years, active cancer and/or 
major surgery in the last 3 months. If patients do not 
have additional risk factors for VTE, LMWH prophylaxis 
can be considered.
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The optimal duration for prophylaxis in non- 
hospitalised patients (if no chronic anticoagulation is 
required) is unknown, but we propose a 14-day treat-
ment. Thereafter, the need for extended thrombopro-
phylaxis should be reassessed.
3.3. Anticoagulation management during 
pregnancy and post-partum period in COVID-19 
positive women
In pregnant women with confirmed COVID-19 but 
without severe symptoms, we recommend against 
thromboprophylaxis if not otherwise indicated.
In pregnant women with severe symptoms (e.g., high 
fever, immobilisation), we recommend 
thromboprophylaxis.
For hospitalised, asymptomatic COVID-19 positive 
pregnant women, we recommend a standard obstetric 
thromboprophylactic risk assessment (based on cur-
rent recommendations [37]). This assessment should 
be repeated if necessary.
For hospitalised, symptomatic COVID-19 positive 
pregnant women, we recommend starting thrombo-
prophylaxis (unless contraindicated).
If VTE is confirmed, we recommend continuing antic-
oagulant treatment (LMWH) for 6 to 8 weeks during 
postpartum with a minimal duration of 3 months [37].
We recommend VTE prophylaxis in postpartum 
women with COVID-19, based on individual risk assess-
ment. In the absence of risk factors requiring antepar-
tum prophylaxis, we do not recommend postpartum 
prophylaxis in asymptomatic or mildly symptomatic 
patients with uncomplicated delivery and no obstetric 
indication for postpartum VTE prophylaxis. If antepar-
tum prophylaxis was given because of COVID-19, we 
recommend continuing prophylaxis for at least 
14 days. After 14 days, the need for anticoagulation 
should be reassessed according to risk-benefit balance 
(severity of COVID infection and other risk factors).
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